Effectiveness and safety of reduced‐dose secukinumab switching to risankizumab for psoriasis patients in Asian population: A case series
Abstract
Dear Editor, The use of biologics in recent decades has revolutionized the treatment of psoriasis. However, the high cost poses a significant barrier to patients who do not have access to reimbursed biologics. Interleukin (IL)17 and IL23 blockers have become the gold standards for psoriasis treatment due to their efficacy and safety, and among them, secukinumab, an IL17A blocker, is the only biologic which can be given in reduced doses (150 mg every 4 weeks after initial loading) according to the package insert in many countries (e.g. US, Japan, Taiwan, etc.) The reduced dose of secukinumab is particularly valuable for patients with lower body weight and those who are biologic naïve.1 A realworld study demonstrated that secukinumab 150 mg (SEC150) and 300 mg (SEC300) had comparable response in Chinese patients. PASI75/90/100 responses were achieved in 100%, 97.8% and 95.7% of patients, respectively, in SEC150 group and 91.5%, 86.4% and 79.9%, respectively, in SEC300 group at week 24.2 Although patients who failed secukinumab may benefit from switching to other biologics,3 the next treatment option with similar pharmacoeconomic consideration is unknown for those who used SEC150. Risankizumab is an IL23 blocker which has also been studied in reduced doses. In the SustaIMM study, PASI75/90 responses were also comparable between patients receiving 75 mg (RZB75, PASI75/90 = 90/76%) and 150 mg (RZB150, PASI75/90 = 95/75%) risankizumab in Japanese population.4 Thus, RZB75 every 12…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.